LONDON, Sept 19 (Reuters) - Novo Nordisk said on Tuesday is has contracted Aspen Pharmacare to produce human insulin on its behalf in South Africa for export to African countries through a low-cost government tender system. The Danish drugmaker said the new contract with Aspen will lead to the production of 16 million vials of insulin next year, marking its "expanded commitment" to improving access to life-saving insulin to people living with diabetes in Africa.
Novo said the amount that Aspen will produce next year under the contract equates to the yearly consumption of 1.1 million people with type 1 and type 2 diabetes. (Reporting by Maggie Fick; Editing by Kirsten Donovan)
